Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Mesothelioma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Malignant Pleural Mesothelioma (33)

Malignant Pleural Mesothelioma (33)

›

No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	cisplatin + raltitrexed Sensitive: A2 - Guideline cisplatin + raltitrexed Sensitive : A2	cisplatin + raltitrexed Sensitive: A2 - Guideline cisplatin + raltitrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + raltitrexed Sensitive: A2 - Guideline carboplatin + raltitrexed Sensitive : A2	carboplatin + raltitrexed Sensitive: A2 - Guideline carboplatin + raltitrexed Sensitive : A2